Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions

2002471 citationsJournal Articlebronze Open Access

Authors

Roberto Corti · Merck & Co., Inc., Rahway, NJ, USA (United States)

Valentı́n Fuster · Merck & Co., Inc., Rahway, NJ, USA (United States)

Zahi A. Fayad · Merck & Co., Inc., Rahway, NJ, USA (United States)

Stephen G. Worthley · Merck & Co., Inc., Rahway, NJ, USA (United States)

Gérard Helft · Merck & Co., Inc., Rahway, NJ, USA (United States)

Donald A. Smith · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

The present study demonstrates that maintained lipid-lowering therapy with simvastatin is associated with significant regression of established atherosclerotic lesions in humans. Our observations indicate that lipid-lowering therapy is associated with sustained vascular remodeling and emphasize the need for longer-term treatment.

Topics & Keywords

Coronary Interventions and Diagnostics Cerebrovascular and Carotid Artery Diseases Lipoproteins and Cardiovascular Health

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 106, Issue 23, pp. 2884-2887

DOI: 10.1161/01.cir.0000041255.88750.f0

Field-Weighted Citation Impact: 33.64